Stockreport

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Monopar Therapeutics Inc.  (MNPR) 
PDF WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical compan [Read more]